

# Immunizations Recommended for Adults Living with Diabetes

Children and adults with diabetes should receive vaccinations according to age-appropriate recommendations. This table provides an overview of the vaccinations that are strongly recommended for adults living with diabetes, as well as the vaccinations that are conditionally recommended for adults living with diabetes based on an individualized assessment of person-centred factors. To advocate for all adults with diabetes, this table is not limited by public nor private coverage of vaccines. Rather, a person with diabetes is encouraged to discuss ALL age-appropriate vaccines with the immunizing clinician. This resource is designed to initiate conversations between people affected by diabetes and diabetes educator clinicians. It is expected that the immunizing clinician would have additional knowledge regarding the brand/type of vaccine to administer as well as the immunization series, interval between vaccine doses, cost/coverage, benefits and potential side effects.

This table does not include recommended immunizations for travel. If a person is travelling, and particularly when the person is at higher risk due to the presence of concurrent conditions, such as diabetes, it is recommended that the person see a health care provider for travel-specific health planning, preferably 6 weeks or more before travel.

This table of adult immunization recommendations is in addition to routine childhood immunizations which are beyond the scope of this table. For a list of routine childhood immunizations and the timing thereof, readers are referred to either the Canadian Immunization Guide<sup>1</sup> and/or to the public immunization schedule specific to the province/territory in which the vaccinee resides<sup>2</sup>.

## Age-Appropriate Vaccine Recommendations for Adults with Diabetes

### Ongoing immunizations: Stay Up-to-Date!

AGE	18	24	26	34	44	50	54	60	64	65	74	75	84 ▶
<b>COVID-19</b> - Annual (some high-risk: 2 doses/y) <sup>3</sup>	Dosing interval: minimum of 3 months from the last COVID-19 vaccine dose. If test-confirmed COVID-19 infection, may consider delaying COVID-19 vaccination for previously vaccinated individuals by 3 months.												
<b>FluShot</b> - Annual <sup>4</sup>													
<b>Tetanus<sup>5</sup> - Diphtheria<sup>6</sup> - Pertussis<sup>7</sup></b>						Booster every 10 years							
<b>One-time immunization series</b>													
<b>Invasive Pneumococcal Disease<sup>8,9</sup></b>	One dose of Pneu-C-21 or Pneu-C-20 is recommended regardless of Pneu-C-13 (Prevnar-13) or Pneu-P-23 (Pneumovax-23) vaccination status.												
<b>Herpes Zoster (Shingles)<sup>10,11</sup></b>	Recombinant zoster vaccine (RZV) recommended. If previous episode of herpes zoster (HZ), or if the person received live zoster vaccine (LZV), vaccinate with RZV after at least one year.												
<b>Respiratory Syncytial Virus<sup>12</sup></b>	Individualize: high-risk populations include diabetes, CKD, and obesity.												
<b>Hepatitis B<sup>13</sup></b>	If not vaccinated in childhood or if medical conditions change, e.g., chronic kidney disease (CKD) with or without dialysis. Most people should be immunized with combined hepatitis A + B vaccine.												

### Additional vaccines (not specific to people with diabetes)

#### One-time (Lifetime / Booster) immunization series

<b>Human Papillomavirus<sup>14</sup></b>	If not previously vaccinated with a complete immunization series.												
<b>Meningococcal-ACYW<sup>15</sup></b>	Booster at 12 - 24 years old, even if previously vaccinated as an infant or toddler.												
<b>Meningococcal-B<sup>15</sup></b>													
<b>Measles<sup>16</sup> - Mumps<sup>17</sup> - Rubella<sup>18</sup></b>	Adults born in or after 1970 should receive one dose of the Measles-Mumps-Rubella (MMR) vaccine.												

■ NACI: Adults with diabetes SHOULD be recommended these vaccines ■ NACI: Adults with diabetes MAY be recommended these vaccines (individualize care)  
 ■ Product monograph/under NACI review: Adults with diabetes MAY be recommended these vaccines

**References:** 1. Government of Canada. Recommended immunization schedules: Canadian Immunization Guide. Available at: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-13-recommended-immunization-schedules.html#p1c12a2>. Accessed November 29, 2024; 2. Government of Canada. Provincial and Territorial Immunization Information. Available at: <https://www.canada.ca/en/public-health/services/provincial-territorial-immunization-information.html>. Accessed December 2, 2024; 3. Government of Canada. COVID-19 vaccines: Canadian Immunization Guide. Available at: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-25-covid-19-vaccine.html>. Accessed March 11, 2025; 4. Government of Canada. Statement on seasonal influenza vaccine for 2024-2025. Available at: <https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-statement-seasonal-influenza-vaccine-2024-2025.html>. Accessed December 2, 2024; 5. Government of Canada. Tetanus toxoid: Canadian Immunization Guide. Available at: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-22-tetanus-toxoid.html#p4c21a6>. Accessed December 2, 2024; 6. Government of Canada. Diphtheria toxoid: Canadian Immunization Guide. Available at: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-4-diphtheria-toxoid.html>. Accessed December 2, 2024; 7. Government of Canada. Pertussis (whooping cough) vaccines: Canadian Immunization Guide. Available at: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-15-pertussis-vaccine.html#p4c14a7>. Accessed December 2, 2024; 8. Government of Canada. Summary of NACI statement on November 15, 2024: Recommendations on the use of pneumococcal vaccines in adults, including PNEU-C-21. Available at: <https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-recommendations-use-pneumococcal-vaccines-adults-pneu-c-21.html>. Accessed December 2, 2024; 9. Government of Canada. Pneumococcal vaccines: Canadian Immunization Guide. Available at: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-16-pneumococcal-vaccine.html>. Accessed December 2, 2024; 10. SHINGRIX Product Monograph. GlaxoSmithKline Inc. Health Canada. Published October 13, 2017. Updated November 15, 2022. Retrieved November 22, 2024. [https://pdf.hres.ca/dpd\\_pmi/0069227.PDF](https://pdf.hres.ca/dpd_pmi/0069227.PDF); 11. Government of Canada. Herpes zoster (shingles) vaccine: Canadian Immunization Guide. Available at: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-8-herpes-zoster-shingles-vaccine.html>. Accessed December 2, 2024; 12. Government of Canada. Summary of NACI statement of March 13, 2025: Updated guidance on respiratory syncytial virus (RSV) vaccines for older adults including the expanded use of RSVPreF3 for individuals 50 to 59 years of age and use of the new mRNA-1345 vaccine. Available at: <https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-updated-guidance-rsv-vaccines-older-adults-including-expanded-use-rsvpre3-individuals-50-59-years-age-use-new-mrna-1345-vaccine.html>. Accessed March 14, 2025; 13. Government of Canada. Hepatitis B vaccines: Canadian Immunization Guide. Available at: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-7-hepatitis-b-vaccine.html>. Accessed December 2, 2024; 14. Government of Canada. Summary of NACI statement of July 24, 2024: Updated recommendations on human papillomavirus vaccines. Available at: <https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-updated-recommendations-hpv-vaccines.html>. Accessed December 2, 2024; 15. Government of Canada. Meningococcal vaccines: Canadian Immunization Guide. Available at: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-13-meningococcal-vaccine.html>. Accessed December 2, 2024; 16. Government of Canada. Measles vaccines: Canadian Immunization Guide. Available at: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-12-measles-vaccine.html>. Accessed December 2, 2024; 17. Government of Canada. Mumps vaccines: Canadian Immunization Guide. Available at: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-14-mumps-vaccine.html>. Accessed December 2, 2024; 18. Government of Canada. Rubella vaccines: Canadian Immunization Guide. Available at: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-20-rubella-vaccine.html>. Accessed December 2, 2024.

